German biotechnology company BioNTech SE (Nasdaq:BNTX), the development partner with Pfizer for a COVID-19 vaccine, on 24 September 2020 joined other leading COVID-19 vaccine developers in ruling out participation in Britain's plans to test experimental inoculations by deliberately infecting trial volunteers.
According to a spokesman of the company, "BioNTech's vaccine candidate is not part of this study."
Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.
AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme, Reuters added.
European Commission approves GSK's Arexvy for adults aged 18 and over
PhotonPharma adds Dr. William Warren to board
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s